EA201491119A1 - Мутант gdf-5 для стимулирования образования хрящей - Google Patents

Мутант gdf-5 для стимулирования образования хрящей

Info

Publication number
EA201491119A1
EA201491119A1 EA201491119A EA201491119A EA201491119A1 EA 201491119 A1 EA201491119 A1 EA 201491119A1 EA 201491119 A EA201491119 A EA 201491119A EA 201491119 A EA201491119 A EA 201491119A EA 201491119 A1 EA201491119 A1 EA 201491119A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formation
carting
stimulating
mutant gdf
gdf
Prior art date
Application number
EA201491119A
Other languages
English (en)
Other versions
EA028554B1 (ru
Inventor
Франк ПЛЕГЕР
Флориан Вагнер
Original Assignee
Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх filed Critical Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх
Publication of EA201491119A1 publication Critical patent/EA201491119A1/ru
Publication of EA028554B1 publication Critical patent/EA028554B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к GDF-5-родственным белкам, обладающим улучшенной способностью стимулировать образование хрящей и сниженной способностью стимулировать образование костной ткани. Новые белки особенно полезны при лечении дефектов хряща, где образование костной ткани является нежелательным.
EA201491119A 2011-12-05 2012-12-05 Мутант gdf-5 для стимулирования образования хрящей EA028554B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11191973.4A EP2602264A1 (en) 2011-12-05 2011-12-05 GDF-5 mutant for inducing cartilage formation
PCT/EP2012/074549 WO2013083649A1 (en) 2011-12-05 2012-12-05 Gdf-5 mutant for inducing cartilage formation

Publications (2)

Publication Number Publication Date
EA201491119A1 true EA201491119A1 (ru) 2014-12-30
EA028554B1 EA028554B1 (ru) 2017-11-30

Family

ID=47278877

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491119A EA028554B1 (ru) 2011-12-05 2012-12-05 Мутант gdf-5 для стимулирования образования хрящей

Country Status (23)

Country Link
US (1) US9718867B2 (ru)
EP (3) EP2602264A1 (ru)
JP (1) JP6185926B2 (ru)
KR (1) KR102067724B1 (ru)
CN (1) CN104039820B (ru)
AU (1) AU2012347305B2 (ru)
BR (1) BR112014013122A2 (ru)
CA (1) CA2856458C (ru)
DK (2) DK3168230T3 (ru)
EA (1) EA028554B1 (ru)
ES (2) ES2708675T3 (ru)
HK (1) HK1198768A1 (ru)
HR (2) HRP20170205T1 (ru)
HU (2) HUE033025T2 (ru)
IN (1) IN2014KN01026A (ru)
LT (2) LT2788374T (ru)
MX (1) MX351809B (ru)
PL (2) PL2788374T3 (ru)
PT (2) PT3168230T (ru)
RS (2) RS58253B1 (ru)
SI (2) SI3168230T1 (ru)
TR (1) TR201901263T4 (ru)
WO (1) WO2013083649A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101639269B1 (ko) 2015-12-02 2016-07-13 주식회사 셀루메드 알칼라인 포스파타아제 어세이를 개선하기 위한 방법
JP2023507007A (ja) 2019-12-18 2023-02-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 疼痛及び軟骨破壊を治療するためのｇｄｆ－５変異体の使用
CN111701075A (zh) * 2020-06-24 2020-09-25 亘元(天津)生物医药科技有限公司 一种软骨修复材料、软骨重建生物支架及制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153654A1 (en) 1993-01-12 1994-07-21 Se-Jin Lee Growth differentiation factor-5
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
ATE319823T1 (de) 1993-12-07 2006-03-15 Inst Genetics Llc Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
DK0955313T3 (da) 1995-04-19 2006-08-21 Bioph Biotech Entw Pharm Gmbh Nyt protein og fremgangsmåde til fremstilling af samme
JPH0931098A (ja) 1995-07-24 1997-02-04 Hoechst Japan Ltd 新規なタンパク質ｈｍｗヒトｍｐ５２
ZA966489B (en) 1995-08-03 1997-02-26 Bioph Biotech Entw Pharm Gmbh New protein human MP52 Arg.
DE19647853A1 (de) 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
EP1074620A1 (en) 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
JP2000119192A (ja) 1998-10-09 2000-04-25 Aventis Pharma Ltd 骨誘導因子アンタゴニスト活性を有する成熟型蛋白質
DE10026713A1 (de) 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
KR100530299B1 (ko) 2003-08-11 2005-11-22 산도즈 게엠베하 변이 세팔로스포린 ｃ 아실라제 및 이를 이용한 7-ａｃａ 제조방법
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
EP1698691A1 (en) * 2005-03-04 2006-09-06 Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH Growth factor mutants with improved biological activity
EP1721909A1 (en) 2005-05-10 2006-11-15 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Growth factor mutants with altered biological attributes
JP2007054013A (ja) 2005-08-26 2007-03-08 Research Institute Of Innovative Technology For The Earth 耐熱性ｌ−スレオニンアルドラ−ゼおよびそれをコードする遺伝子
ATE553123T1 (de) * 2005-11-18 2012-04-15 Bioph Biotech Entw Pharm Gmbh Wachstumsfaktormutanten mit hoher aktivität
PL1999152T3 (pl) 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
EP2949338B1 (en) 2010-08-20 2017-10-25 Wyeth LLC Designer osteogenic proteins

Also Published As

Publication number Publication date
EA028554B1 (ru) 2017-11-30
ES2630853T3 (es) 2017-08-24
ES2708675T3 (es) 2019-04-10
RS58253B1 (sr) 2019-03-29
SI2788374T1 (sl) 2017-04-26
DK3168230T3 (en) 2019-01-14
RS55686B1 (sr) 2017-07-31
MX2014006465A (es) 2015-03-20
US9718867B2 (en) 2017-08-01
JP6185926B2 (ja) 2017-08-23
DK2788374T3 (en) 2017-04-10
PT3168230T (pt) 2019-01-30
EP2788374B1 (en) 2017-01-04
EP2788374A1 (en) 2014-10-15
IN2014KN01026A (ru) 2015-10-09
PT2788374T (pt) 2017-02-15
US20140369978A1 (en) 2014-12-18
PL3168230T3 (pl) 2019-06-28
CN104039820B (zh) 2018-01-09
AU2012347305B2 (en) 2016-11-03
KR102067724B1 (ko) 2020-01-17
LT3168230T (lt) 2019-03-12
MX351809B (es) 2017-10-30
AU2012347305A1 (en) 2014-06-26
CA2856458C (en) 2024-03-12
LT2788374T (lt) 2017-02-10
KR20140100969A (ko) 2014-08-18
HUE042191T2 (hu) 2019-06-28
CN104039820A (zh) 2014-09-10
HK1198768A1 (en) 2015-06-05
JP2015504649A (ja) 2015-02-16
WO2013083649A1 (en) 2013-06-13
EP3168230B1 (en) 2018-12-05
CA2856458A1 (en) 2013-06-13
BR112014013122A2 (pt) 2020-10-27
PL2788374T3 (pl) 2017-08-31
HRP20190160T8 (hr) 2020-02-07
EP3168230A1 (en) 2017-05-17
EP2602264A1 (en) 2013-06-12
HRP20190160T1 (hr) 2019-03-22
TR201901263T4 (tr) 2019-02-21
SI3168230T1 (sl) 2019-03-29
HRP20170205T1 (hr) 2017-06-16
HUE033025T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201300116A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201300713A1 (ru) Варианты, происходящие из actriib, и их применение
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201171200A1 (ru) Полиморфы элтромбопага и солей элтромбопага, а также способы их получения
MX343640B (es) Promotor de osteogenesis.
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
ATE500855T1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
EA201101111A1 (ru) Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU